image description

Stopping
cancer requires understanding the patient’s tumor expression

image description

Stopping cancer requires
new targets

image description

Stopping
cancer requires new therapies and new combinations

image description

Stopping cancer
is our mission

image description

DKN-01
an anti-DKK1
antibody

A new targeted therapy in development for cancer patients with DKK1 expressing tumors

learn more
image description

Join our team

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. Leap has a strong financial position and in September 2021 closed a public offering with gross proceeds to Leap of approximately $104 million. Leap is based in Cambridge, MA.

image description
image description